MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.amjmed.2018.10.013

Медицинская библиотека · The American journal of medicine · 2018

Canakinumab: Promises and Future in Cardiometabolic Diseases and Malignancy.

Dhorepatil Aneesh, Ball Somedeb, Ghosh Raktim K, Kondapaneni Meera, Lavie Carl J

СтатьяОбзорПеревод пока не подготовлен

Аннотация

Inflammation has proven in multiple studies to be responsible for the progression of cardiometabolic diseases and malignancies. The interleukin family has been critically associated with progression of atherosclerosis, insulin resistance, and various malignancies. Given the advent of pharmacologic interleukin-1 (IL-1) inhibition, this pathway can potentially be targeted to improve outcomes. In the recently concluded Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) trial, investigators looked at the potential role of IL-1 (especially IL-1β) inhibition in halting the progression of atherosclerosis. In the subset analysis of the data from this trial, IL-1β inhibition with canakinumab was found to have beneficial effects in other cardiometabolic diseases characterized by inflammation, like diabetes, stroke, and chronic kidney disease, and also in patients with lung cancer. In this article, we will try to review the current literature on the role of canakinumab in the treatment of cardiometabolic diseases and malignancies.

Для цитирования: Dhorepatil Aneesh, Ball Somedeb, Ghosh Raktim K, Kondapaneni Meera, Lavie Carl J. Canakinumab: Promises and Future in Cardiometabolic Diseases and Malignancy.. The American journal of medicine. 2018. DOI: 10.1016/j.amjmed.2018.10.013.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.